Advertisement
UK markets close in 2 hours 33 minutes
  • FTSE 100

    8,217.62
    -30.17 (-0.37%)
     
  • FTSE 250

    20,292.39
    -71.04 (-0.35%)
     
  • AIM

    765.50
    -2.53 (-0.33%)
     
  • GBP/EUR

    1.1838
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2644
    -0.0042 (-0.33%)
     
  • Bitcoin GBP

    48,611.94
    +401.36 (+0.83%)
     
  • CMC Crypto 200

    1,272.52
    -11.26 (-0.88%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.24
    +0.41 (+0.51%)
     
  • GOLD FUTURES

    2,326.00
    -4.80 (-0.21%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,098.64
    -78.98 (-0.43%)
     
  • CAC 40

    7,584.19
    -78.11 (-1.02%)
     

Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta

FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017.   REUTERS/Brian Snyder/File Photo
FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo

Thomson Reuters

(Reuters) - Biogen Inc and AbbVie Inc have withdrawn their multiple sclerosis drug worldwide due to safety issues, the companies said on Friday.

The withdrawal of marketing authorizations for the drug, Zinbryta, followed reports of inflammation of the membranes of the brain in some patients.

Zinbryta, a self-administered, under-the-skin injection designed to treat adults with relapsing forms of multiple sclerosis was approved by U.S. regulators in 2016.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar)

See Also: